Skip to content
OpenCapital
Get started

CRISPR Therapeutics CRSP Collaborative Arrangement Material Rights — Milestone Payment Receivable

Similar metrics at other companies

Dianthus Therapeutics logo
DNTHMilestone — Revenue Recognition Milestone Method Pending
$15M0.0%
Dianthus Therapeutics logo
DNTHMilestone — Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer
$7M+600%
Rivian Automotive, Inc. logo
RIVNTesting Milestone Payments — Receivable, contingent on milestone achievement
$1B0.0%
Rivian Automotive, Inc. logo
RIVNStart of Production Milestone Payments — Receivable, contingent on milestone achievement
$460M—
Insmed logo
INSMPayment Of Milestone
$15M—
Axsome Therapeutics logo
AXSMMilestone Revenue — Revenue
$500K—

Other financials

Income statement

See full
Revenue$1.5M+68.6%
Operating income-$130.2M+12.2%
Net income-$122.9M+9.6%
EPS (diluted)-$1.28+19.0%

Balance sheet

See full
Cash & equivalents$423.3M+80.0%
Total debt$787.6M+259%
Total equity$1.8B-0.8%
Total assets$2.7B+25.8%

Cash flow

See full
Operating cash flow-$108.9M-102%
CapEx$504.0K+145%
Free cash flow-$109.4M-102%

Valuation

See full
Market cap$5.33B+56.4%
Enterprise value$5.69B+69.8%
P/S1,298.3×+1,208×

Profitability

See full
Operating margin-15,754.2%-17,253pp
Net margin-13,856.5%-15,058pp
FCF margin-9,777.6%-10,759pp

Returns & leverage

See full
Return on equity-31.2%+43.7pp
Debt / equity0.4×+0.3×
Current ratio18×+2.3×

Where this comes from

Reported directly by CRISPR Therapeutics in its filing.

Tagged under the XBRL concept crsp:MilestonePaymentReceivable.

The official record: CRISPR Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about CRISPR Therapeutics's collaborative arrangement material rights — milestone payment receivable.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CRISPR Therapeutics's collaborative arrangement material rights — milestone payment receivable?
CRISPR Therapeutics (CRSP) reported collaborative arrangement material rights — milestone payment receivable of $410M in Q1 2026.
How has CRISPR Therapeutics's collaborative arrangement material rights — milestone payment receivable changed year-over-year?
CRISPR Therapeutics's collaborative arrangement material rights — milestone payment receivable decreased by 0.0% year-over-year, from $410M to $410M.
What is the long-term trend for CRISPR Therapeutics's collaborative arrangement material rights — milestone payment receivable?
Over 3 years (2021 to 2024), CRISPR Therapeutics's collaborative arrangement material rights — milestone payment receivable has grown at a 0.0% compound annual growth rate (CAGR), from $1.64B to $1.64B.
What does collaborative arrangement material rights — milestone payment receivable mean?
Represents the value of milestone payments earned under collaborative research and development agreements that are currently due or expected to be received. This metric tracks the realization of specific scientific or regulatory achievements within a partnership. It serves as a key indicator of the company's progress in hitting development targets that trigger contractual cash inflows.